NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SMMT

Summit Therapeutics Inc

Jun 30 • 04:00PM ET

21.28

Dollar change +0.68
Percentage change 3.30	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD NBIX ALNY BIIB AMGN SRPT AKTX PRTA

| Held by: VTI VB XBI VXF VBR IWP IBB SCHA IWF VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.33	Insider Own	84.99%	Shs Outstand	741.61M	Perf Week	4.36%
Market Cap	15.80B	Forward P/E	-	EPS next Y	-0.54	Insider Trans	0.00%	Shs Float	111.44M	Perf Month	-18.81%
Enterprise Value	15.45B	PEG	-	EPS next Q	-0.09	Inst Own	13.16%	Short Float	27.40%	Perf Quarter	4.72%
Income	-240.75M	P/S	-	EPS this Y	-30.60%	Inst Trans	5.66%	Short Ratio	6.13	Perf Half Y	12.00%
Sales	0.00M	P/B	45.83	EPS next Y	-32.33%	ROA	-85.89%	Short Interest	30.53M	Perf YTD	19.25%
Book/sh	0.46	P/C	43.70	EPS next 5Y	-23.20%	ROE	-123.93%	52W High	36.91 -42.35%	Perf Year	173.87%
Cash/sh	0.49	P/FCF	-	EPS past 3/5Y	31.56% -10.52%	ROIC	-69.33%	52W Low	6.78 213.86%	Perf 3Y	1783.19%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.29% 7.75%	Perf 5Y	520.41%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-99.70%	Oper. Margin	-	ATR (14)	1.51	Perf 10Y	99.81%
Dividend Ex-Date	-	Quick Ratio	10.63	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	49.41	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	10.63	EPS Q/Q	-37.64%	SMA20	4.39%	Beta	-1.03	Target Price	34.10
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-8.98%	Rel Volume	0.43	Prev Close	20.60
Employees	159	LT Debt/Eq	0.01	Earnings	May 01 AMC	SMA200	1.28%	Avg Volume	4.98M	Price	21.28
IPO	Mar 05, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.23% -	Trades		Volume	2,135,787	Change	3.30%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Initiated	Leerink Partners	Underperform	$12
Mar-26-25	Upgrade	Citigroup	Neutral → Buy	$23 → $35
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform	$30
Feb-28-25	Initiated	Goldman	Buy	$42
Jan-08-25	Initiated	Truist	Buy	$35
Dec-11-24	Initiated	Wells Fargo	Overweight	$30
Dec-06-24	Initiated	Jefferies	Buy	$31
Nov-04-24	Initiated	JMP Securities	Mkt Outperform	$32
Sep-27-24	Downgrade	Citigroup	Buy → Neutral	$19 → $23
Aug-12-24	Initiated	H.C. Wainwright	Buy	$16
May-07-24	Initiated	Citigroup	Buy	$7
Mar-26-24	Initiated	Stifel	Buy	$8
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy	$30 → $27
Feb-13-18	Initiated	BTIG Research	Buy	$33
Jan-04-18	Initiated	SunTrust	Buy	$24
Dec-01-17	Resumed	H.C. Wainwright	Buy	$16
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform	$26 → $29

Show Previous Ratings

Today 08:00AM	Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors (Business Wire)
Jun-25-25 06:30PM	H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target (Insider Monkey)
09:59AM	Merck Moves Past 50-Day Average: How to Play MRK Stock Now (Zacks)
Jun-11-25 05:28PM	Why Summit Therapeutics Stock Tanked Today (Motley Fool) -11.32%
Jun-10-25 09:46AM	Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE? (Zacks)
10:18AM	Loading…
Jun-09-25 10:18AM	Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip? (Zacks)
Jun-06-25 04:44PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 08:00AM	Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
05:52AM	Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday (Insider Monkey)
03:19AM	2 Soaring Stocks Wth More Upside Potential (Motley Fool)
Jun-04-25 07:26AM	Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday (Insider Monkey) -5.14%
Jun-03-25 09:35AM	Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround (Zacks) +16.33%
Jun-02-25 11:46AM	Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results (Zacks)
11:39AM	Bristol Myers Joins Pharma's Hottest Horserace in $11.1B Deal With BioNTech (Barrons.com)
08:07AM	Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal (Bloomberg)
07:00AM	Loading…
07:00AM	3 No-Brainer Healthcare Stocks to Buy in June (Motley Fool)
05:23AM	Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? (Motley Fool)
May-30-25 02:19PM	Why Summit Therapeutics Plunged Today (Motley Fool) -30.50%
09:27AM	Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. (Barrons.com)
09:22AM	Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure (Investor's Business Daily)
06:50AM	New Summit data could slow US approval plans for PD-1/VEGF drug (BioPharma Dive)
06:00AM	Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study (Business Wire)
May-26-25 11:01AM	MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock? (Zacks)
09:55AM	Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect? (Zacks)
May-24-25 06:40AM	3 High-Flying Stocks That Could Soar Even More (Motley Fool)
May-21-25 02:22PM	Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal (Insider Monkey)
04:48AM	Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 (Motley Fool)
May-20-25 10:46AM	Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. (Barrons.com)
08:46AM	Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech (Zacks)
May-18-25 05:47AM	Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money (Motley Fool)
04:30PM	Loading…
May-16-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-25 10:37AM	Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-07-25 09:30AM	Can Summit Therapeutics Stock Double Your Money? (Motley Fool)
May-06-25 09:55AM	Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know (Zacks) -13.63%
May-04-25 05:39AM	Why Summit Therapeutics Inc. (SMMT) Soared Last Week (Insider Monkey)
May-02-25 09:01AM	Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil (Zacks) +13.09%
08:30AM	This Soaring Stock Just Delivered More Good News. Time to Buy? (Motley Fool)
01:06AM	Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
May-01-25 04:09PM	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 (Business Wire)
Apr-28-25 07:48AM	Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat? (Zacks)
Apr-26-25 12:50PM	Akeso survival data for ivonescimab misses expectations, STAT says (TipRanks)
09:30AM	Summit Therapeutics: New Ivonescimab Data Raise Concerns (Seeking Alpha)
Apr-25-25 05:05PM	Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today (Motley Fool) -36.06%
02:50PM	Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China (Business Wire)
Apr-24-25 04:15PM	Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 (Business Wire) +10.44%
08:00AM	Akeso and Summit notch another Phase III win with their Keytruda competitor (Clinical Trials Arena)
Apr-23-25 06:13PM	Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday (Insider Monkey) +21.50%
04:10PM	BioNTech Surges On Summit's Coattails. But Can They Take On Merck? (Investor's Business Daily)
04:05PM	Why Summit Therapeutics Rocketed Double-Digits Today (Motley Fool)
03:47PM	Why Is Summit Therapeutics Stock Soaring On Wednesday? (Benzinga)
06:15AM	Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China (Business Wire)
05:45AM	This Company's Co-CEOs Just Bought More Shares. Should You? (Motley Fool)
Apr-22-25 07:32AM	Merck Q1 Earnings Coming Up: Should You Buy the Stock Now? (Zacks) +8.45%
Apr-20-25 10:15AM	Bullish On Akeso's Ivonescimab, But Valuation And Geopolitical Risks Remain (Seeking Alpha)
Apr-19-25 07:40AM	What Moved Markets This Week (Seeking Alpha)
Apr-15-25 12:40AM	Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? (Insider Monkey) -5.78%
Apr-14-25 09:08AM	Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition (Seeking Alpha) +12.44%
05:57AM	Here's Why Summit Therapeutics Stock Soared 15% on Friday (Zacks)
Apr-12-25 06:45PM	Why Summit Therapeutics Inc. (SMMT) Soared Last Week? (Insider Monkey)
02:45PM	3 Magnificent Stocks That Could Double or More by 2030 (Motley Fool)
12:35PM	Summit Therapeutics: Not Pharmacyclics, Not Yet (Seeking Alpha)
02:10AM	Why Summit Therapeutics Inc. (SMMT) Surged On Friday? (Insider Monkey)
Apr-11-25 12:15PM	Summit co-CEO option exercise quite bullish, says Cantor Fitzgerald (TipRanks) +15.33%
12:10PM	Expert says Summits HARMONi-2 study could beat expectations, says Truist (TipRanks)
06:46AM	Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday? (Insider Monkey)
Apr-10-25 04:36PM	Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets (Motley Fool) +10.53%
Apr-06-25 07:02AM	2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade (Motley Fool)
Apr-04-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.20%
Apr-03-25 11:30AM	Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? (Zacks) -7.58%
09:45AM	3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months (Motley Fool)
Mar-31-25 03:25PM	Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today (Motley Fool) -5.07%
04:53AM	Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. (Motley Fool)
Mar-30-25 11:35AM	Street Calls of the Week (Investing.com)
Mar-28-25 11:30AM	Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? (Zacks)
07:30AM	Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade) (Seeking Alpha)
Mar-26-25 05:21PM	Why Summit Therapeutics Stock Slipped Today (Motley Fool)
09:28AM	Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook (SeekingAlpha)
Mar-23-25 05:49AM	Is Summit Therapeutics a Millionaire Maker? (Motley Fool)
Mar-21-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-19-25 10:11AM	Merck Loses Almost $52B in 6 Months: How to Play MRK Stock (Zacks)
09:00AM	This Unstoppable Biotech Stock Just Became an Even Better Buy (Fool)
Mar-17-25 04:24PM	Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer (Business Wire)
Mar-14-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.34%
08:13AM	Why Summit Therapeutics Stock Was Winning This Week (Motley Fool)
Mar-13-25 07:04PM	Is Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025? (Insider Monkey)
07:30AM	This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year (Motley Fool)
Mar-08-25 06:39PM	Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? (Insider Monkey)
Mar-04-25 01:00AM	Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda (BioPharma Dive)
Feb-27-25 01:14PM	Summit Therapeutics Inc. (SMMT): Among the Stocks That Will Go to the Moon According to Analysts (Insider Monkey)
Feb-25-25 11:17AM	Why Summit Therapeutics Inc. (SMMT) Went Down On Monday? (Insider Monkey)
03:56AM	Q4 2024 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:01AM	Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Feb-24-25 12:52PM	Pfizer sets sights on Summits bispecific in combo with its ADCs (Pharmaceutical Technology) -14.83%
12:43PM	Is Summit Therapeutics (SMMT) One of the Best Growth Stocks to Invest In According to Analysts? (Insider Monkey)
10:13AM	Summit Therapeutics Stock Sinks as Firm Reports Widening Loss (Investopedia)
06:05AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024 (Business Wire)
06:00AM	Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs) (Business Wire)
Feb-18-25 09:00AM	Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025 (Business Wire)
Feb-17-25 04:32AM	3 Stocks That Could Trounce the Market in 2025 (Motley Fool)
Feb-14-25 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zanganeh Mahkam	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 05:01 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SMMT

Summit Therapeutics Inc

Upgrade your FINVIZ experience